HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Consumer Health Product Recalls For Jan. 20-Feb. 3

This article was originally published in The Tan Sheet

Executive Summary

Recalls reported by FDA for OTC drugs, nutritionals and personal care products.

You may also be interested in...



Perrigo’s Latest Woe: Empty Emergency Contraceptive Packages Recalled

Perrigo is recalling is Option 2 (levonorgestrel 1.5 mg) emergency contraceptive in US and Canada because the tablet is missing from some of 181,776 one-count packages.

Perrigo’s Latest Woe: Empty Emergency Contraceptive Packages Recalled

Perrigo is recalling is Option 2 (levonorgestrel 1.5 mg) emergency contraceptive in US and Canada because the tablet is missing from some of 181,776 one-count packages.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel